Company Overview: Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA)

http://dicerna.com/ SCN's Jane King interviews Douglas M. Fambrough, Ph.D., President & CEO of Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA). They discuss the biopharmaceutical company and its exciting proprietary drug platform GalXC™
Dicerna is an RNA interference-based biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver and for other therapeutic areas in which the liver plays a key role including cardiovascular disease, chronic liver diseases, and liver infectious diseases.
• Their proprietary RNAi technology uses the body’s natural biological pathways to silence or “turn off” genes with a high degree of selectivity and specificity.

Видео Company Overview: Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) канала BGN - Blockchain Global News